BiotechTube

PTH134 + Placebo + Forsteo

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Post-menopausal Osteoporosis

Conditions

Post-menopausal Osteoporosis

Trial Timeline

Sep 1, 2010 → —

NCT ID
NCT01224717

About PTH134 + Placebo + Forsteo

PTH134 + Placebo + Forsteo is a phase 1 stage product being developed by Novartis for Post-menopausal Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01224717. Target conditions include Post-menopausal Osteoporosis.

What happened to similar drugs?

8 of 15 similar drugs in Post-menopausal Osteoporosis were approved

Approved (8) Terminated (0) Active (7)
✅raloxifene + PlaceboEli LillyApproved
✅Teriparatide + Zoledronic AcidEli LillyApproved
✅Raloxifene + Raloxifene + PlaceboEli LillyApproved
✅TeriparatideEli LillyApproved
✅ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva] + AlendronateRocheApproved
✅ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva]RocheApproved
✅ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva]RocheApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01224717Phase 1Completed

Competing Products

19 competing products in Post-menopausal Osteoporosis

See all competitors
ProductCompanyStageHype Score
raloxifene + PlaceboEli LillyApproved
43
teriparatide 20 micrograms/day subcutaneous + calcitonin 100 IU/day subcutaneousEli LillyPhase 3
40
Teriparatide + Zoledronic AcidEli LillyApproved
43
teriparatideEli LillyPhase 3
40
Raloxifene + Raloxifene + PlaceboEli LillyApproved
43
TeriparatideEli LillyApproved
43
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3
40
MK0429MerckPhase 2
35
Placebo + Zoledronic acidNovartisPhase 3
40
zoledronic acid + Any oral bisphosphonates marketed in CanadaNovartisPre-clinical
26
ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva] + AlendronateRocheApproved
43
ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva]RocheApproved
43
ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva]RocheApproved
43
Placebo + ibandronate [Bonviva/Boniva]RocheApproved
43
ibandronate [Bonviva/Boniva] + PlaceboRochePhase 3
40
IbandronateRochePhase 3
40
romosozumab HCP administration with PFSAmgenPhase 3
40
Romosozumab + Alendronate (Fosamax) + Placebo Romosozumab + Placebo AlendronateAmgenPhase 2
42
BAY3427080 + Placebo (for BAY3427080)BayerPhase 1/2
29